SAB Biotherapeutics (SABS) PT Raised to $13 at Jefferies

June 15, 2026 2:31 PM

Jefferies analyst Roger Song raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $13.00 (from $11.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found